The Disease
Our Mission and Impact
Supporting Families, Advancing Research, and Raising Hope
What Is Ataxia-Pancytopenia Syndrome (ATXPC)?
Ataxia-Pancytopenia Syndrome (ATXPC) is a rare genetic condition caused by pathogenic mutations in the SAMD9L gene, which disrupt normal cellular functions, particularly affecting the circulatory, immune, and nervous systems. These mutations impair cellular proliferation and DNA protection, leading to serious health issues such as low blood counts (pancytopenia), cerebellar ataxia (loss of muscle control), and, in some cases, increased infection risk and autoinflammatory diseases across multiple organ systems. Bone marrow failure, most commonly manifesting as Myelodysplasia Syndrome (MDS), is often the first clinical presentation during childhood, while cerebellar ataxia typically develops later.
How ATXPC Is Diagnosed
Diagnosis usually begins in pediatric Hematology-Oncology clinics when abnormal blood counts are detected; further genetic testing is performed to identify SAMD9L mutations, now recognized as one of the most common causes of Inherited Bone Marrow Failure Syndromes (IBMFS). While pediatric clinics increasingly recognize SAMD9L, many adults remain undiagnosed until after their children are tested. Some patients may experience somatic reversion, where certain blood cells lose the mutation and temporarily improve, but this phenomenon does not prevent the long-term neurological decline caused by the mutation.
Symptoms and Disease Progression
The prevalence of pathogenic SAMD9L mutations remains uncertain because many cases are missed due to limited genetic testing and varying clinical presentations. However, it is estimated that 9–18% of pediatric bone marrow failure patients carry mutations in this gene. Pediatric neurologists may also uncover SAMD9L mutations when investigating unexplained movement disorders. Not all individuals with a SAMD9L mutation exhibit both hematological and neurological symptoms, but the risk is high enough to require close monitoring of both systems. Symptoms typically include difficulty walking, loss of coordination, frequent infections, chronic fatigue, easy bleeding, and cognitive slowing. Imaging studies often reveal progressive white matter lesions in the brain, correlating with motor and cognitive decline. Additionally, patients may experience systemic auto-inflammatory diseases, developmental delays, and metabolic impairments.
Current Research and Treatment Efforts
First described clinically in 1978 and genetically linked to SAMD9L mutations in 2016, ATXPC research has since expanded. Scientists are now investigating how mutations alter protein translation, cellular pathways, and immune responses (such as Interferon signaling). Although bone marrow transplantation and supportive therapies like IVIG can manage some symptoms, no current treatment directly targets the neurological complications of ATXPC. Therapeutic innovation, including gene-targeted approaches such as antisense oligonucleotide (ASO) therapies, is actively being explored. However, progress remains slow due to the disease’s rarity, and advancements heavily depend on patient-led advocacy and funding. The future for SAMD9L patients rests not only in the hands of scientists but in the collective will of motivated communities pushing research forward.
For those interested in deeper scientific understanding, recent publications explore SAMD9L’s role in bone marrow failure, neurological degeneration, and therapeutic mechanisms. Research includes topics such as spontaneous remission and monosomy 7 reversal, immune dysfunction, and genetic predispositions to myeloid malignancies. To learn more, you can review scientific articles from sources like Experimental Hematology, Blood Journal, Movement Disorders, and others, or visit OMIM and Rare Disease Day pages for additional resources.
